BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32236308)

  • 21. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
    Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
    J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
    Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
    Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
    [No Abstract]   [Full Text] [Related]  

  • 24. Thyroid Lobectomy for T1 Papillary Thyroid Carcinoma in Pediatric Patients.
    Sudoko CK; Jenks CM; Bauer AJ; Isaza A; Mostoufi-Moab S; Surrey LF; Bhatti TR; Franco A; Adzick NS; Kazahaya K
    JAMA Otolaryngol Head Neck Surg; 2021 Nov; 147(11):943-950. PubMed ID: 34554217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.
    Matsuzu K; Sugino K; Masudo K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Uruno T; Suzuki A; Magoshi S; Akaishi J; Masaki C; Kawano M; Suganuma N; Rino Y; Masuda M; Kameyama K; Takami H; Ito K
    World J Surg; 2014 Jan; 38(1):68-79. PubMed ID: 24081532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
    Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
    Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
    World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifocality Is not an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score-Matching Analysis.
    Geron Y; Benbassat C; Shteinshneider M; Or K; Markus E; Hirsch D; Levy S; Ziv-Baran T; Muallem-Kalmovich L
    Thyroid; 2019 Apr; 29(4):513-522. PubMed ID: 30799769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of microscopic extra-nodal extension (ENE) on locoregional recurrence following curative surgery for papillary thyroid carcinoma.
    Lang BH; Shek TW; Wan KY
    J Surg Oncol; 2016 Apr; 113(5):526-31. PubMed ID: 26792294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lateral neck metastases in the ipsilateral and contralateral compartments of papillary thyroid carcinoma located in one lobe.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    ANZ J Surg; 2019 Nov; 89(11):E498-E501. PubMed ID: 31566299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.
    Feng JW; Pan H; Wang L; Ye J; Jiang Y; Qu Z
    J Endocrinol Invest; 2020 May; 43(5):601-613. PubMed ID: 31749082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.
    Ahn JH; Kwak JH; Yoon SG; Yi JW; Yu HW; Kwon H; Kim SJ; Lee KE
    Surgery; 2022 Jan; 171(1):182-189. PubMed ID: 34391573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic characteristics and outcomes of papillary thyroid carcinoma in younger patients.
    Lu Y; Jiang L; Chen C; Chen H; Yao Q
    Medicine (Baltimore); 2020 Apr; 99(15):e19795. PubMed ID: 32282744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
    Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasound-Guided Radiofrequency Ablation
    He H; Wu R; Zhao J; Song Q; Zhang Y; Luo Y
    Front Endocrinol (Lausanne); 2021; 12():734432. PubMed ID: 34512557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
    Furtado Mde S; Rosario PW; Calsolari MR
    Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
    Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
    Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Model Incorporating Clinicopathological Characteristics of Delphian Lymph Node Metastasis Risk Profiles in Papillary Thyroid Cancer.
    Li X; Duan Y; Liu D; Liu H; Zhou M; Yue K; Shuai Y; Wang Y; Ji C; Jing C; Wu Y; Wang X
    Front Endocrinol (Lausanne); 2021; 12():591015. PubMed ID: 33841323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive Factors of Central-Compartment Lymph Node Metastasis for Clinical N0 Papillary Thyroid Carcinoma With Strap Muscle Invasion.
    Xue S; Zhang L; Pang R; Wang P; Jin M; Guo L; Zhou Y; Dong B; Chen G
    Front Endocrinol (Lausanne); 2020; 11():511. PubMed ID: 33013682
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.